Amadix
Amadix develops blood-based diagnostic tests for the early detection of various cancers, including colorectal, lung, and pancreatic types. Its primary product, PreveCol, uses a high-precision algorithm combining biomarkers and clinical characteristics to identify colorectal cancer and advanced adenomas. The company also utilizes artificial intelligence and advanced data analytics to develop predictive models for personalized medicine and oncology screening.
Visit websiteMadrid, Spain
Biotechnology
Diagnostics
Oncology
Healthtech
Artificial Intelligence
Funding summary
- Total raised
- €5.7M
- Funding rounds
- 3
Investors in Amadix
Investors on record for Amadix. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Amadix?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors